AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
about
P1343
Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton InvolvementMutation analysis of inhibitory guanine nucleotide binding protein alpha (GNAI) loci in young and familial pituitary adenomas.Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell LinecAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.The genetic background of acromegaly.Genetics of gigantism and acromegaly.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.The Complex Biology of the Aryl Hydrocarbon Receptor and Its Role in the Pituitary Gland.A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenomaAIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation.Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland.Somatotroph-Specific Aip-Deficient Mice Display Pretumorigenic Alterations in Cell-Cycle Signaling.Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?Genetics of Cushing's Syndrome.Interaction of AIP with protein kinase A (cAMP-dependent protein kinase).Screening for germline KCNQ1 and KCNE2 mutations in a set of somatotropinoma patients.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclaturePituitary Gene Signalling Pathway
P2860
Q26770701-8026CAC7-6B79-41E0-9AC2-F36BD727065EQ34301711-F715EA9D-A5C3-4B46-BFEE-3CC54A49643AQ36153987-78BCD8EC-9486-45B3-A248-D6E6ECDDEFBCQ36991419-605B89FF-C102-4967-9AE2-20299E48506EQ37678059-CDBBB5F6-4881-4D4A-94F6-E9840FD4CDD7Q38961684-D2A88248-4D0F-4F7A-9EAD-4E73CC48F8D6Q38990078-1FD4480F-1803-47C1-BADF-9188310D294DQ39387486-F4C734ED-18E7-4186-8BD4-229C8FA05852Q42162920-246ED46F-12B5-482B-B326-797EDBA00D77Q47124521-53BD3A1C-8A2C-467D-9826-B4B31DB1255CQ52672961-0C9A9346-F884-4B4C-B39D-6F2ED4C25669Q52738997-D0575C8D-A3FF-4052-A50A-E635CC679639Q53487796-D71226C5-5E6E-4791-B118-14D0AC5455E1Q53683262-DC820ACC-EA39-4B9C-9433-FF4D2AF02D8FQ54979751-A5DDC6FE-5FC1-40E7-89A8-C7E5DA51B3AEQ55440607-361EE6A2-7122-4943-B98E-D3DF954947CEQ57144951-779CB51E-8151-456B-AC83-08A4DBE21EC7Q58616038-30DC13DF-846C-42E7-8363-92FFB42C9362
P2860
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@en
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@nl
type
label
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@en
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@nl
prefLabel
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@en
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@nl
P2093
P2860
P356
P1433
P1476
AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.
@en
P2093
C Schalin-Jäntti
E Heliövaara
H J Lehtonen
I Tuominen
L Kivipelto
P2860
P2888
P304
P356
10.1038/ONC.2014.50
P407
P577
2014-03-24T00:00:00Z